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ABSTRACT 
IL-11 has been detected in inflamed joints; however its role in the pathogenesis of arthritis is not 
yet clear. Studies were conducted to characterize the expression and functional significance of 
IL-11 and IL-11R in rheumatoid arthritis (RA). IL-11 levels were elevated in RA synovial fluid 
(SF) compared to osteoarthritis (OA) SF and plasma from RA, OA and normal individuals 
(NLs). Morphologic studies established that IL-11 was detected in lining fibroblasts and 
macrophages in addition to sublining endothelial cells and macrophages at higher levels in RA 
compared to NL synovial tissues (STs). Since IL-11R was exclusively expressed in RA 
fibroblasts and endothelial cells, macrophages were not involved in IL-11 effector function. 
Ligation of IL-11 to IL-11Rstrongly provoked fibroblast infiltration into RA joint, while cell 
proliferation was unaffected by this process. Secretion of IL-8 and VEGF from IL-11 activated 
RA fibroblasts was responsible for the indirect effect of IL-11 on endothelial cell transmigration 
and tube formation. Moreover, IL-11 blockade impaired RA SF capacity to elicit endothelial cell 
transmigration and tube formation. We conclude that IL-11 binding to endothelial IL-11R can 
directly induce RA angiogenesis. In addition, secretion of proangiogenic factors from migrating 
fibroblasts potentiated by IL-11 can indirectly contribute to RA neovascularization.  
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INTRODUCTION 
IL-11 belongs to the IL-6 family of cytokines comprised of leukemia inhibitory factor 
(LIF), oncostatin M (OSM), ciliary inhibitory factor (CNTF), cardiotropin-1 (CT-1), 
cardiotrophin-like related cytokine factor 1/neurotrophin-1/B-cell stimulating factor 3 (NNT-1), 
neuropoietin (NPN), IL-27 and IL-31 [1, 2]. Initially, IL-11 was discovered in the culture media 
of a primate bone marrow derived stromal cell line, as a cytokine that induced formation and 
development of blood cells, and it was subsequently cloned in 1990 [3, 4]. A variety of cell types 
have been reported to secrete IL-11 including epithelial cells, fibroblasts, osteoblasts, lung 
smooth muscle cells, neurons, endothelial cells and endometrial cells [5]. IL-11 activates 
JAK/STAT and PI3K/AKT/mTORC1 pathways through heterodimerization of IL-11R and 
gp130 [5, 6].  
IL-11 plays an important role in a number of physiological functions. IL-11 alone or in 
synergy with IL-3 and stem cell factor participates in production of red blood cells [7]. 
Moreover, IL-11 together with IL-13 and IL-4 can increase the frequency of myeloid progenitor 
cell differentiation into macrophages [8]. Consistent with these observations, IL-11 
administration in a clinical trial resulted in increased bone marrow cellularity which was due to 
enhanced number of circulating immature red blood cells and myeloid progenitor cells [9].  
Pathological overexpression of IL-11 occurs in cancers of epithelial cell origin as well as in a 
number of autoimmune diseases [10, 11]. Elevated levels of IL-11 and IL-11R were detected in 
colorectal and prostate carcinoma, and serum IL-11 has been proposed as a potential marker for 
prostate cancer [12, 13]. In multiple sclerosis (MS), IL-11 induces TH-17 cell differentiation and 
expansion of memory TH-17 cells [14].  
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Data concerning the role of IL-11 in preclinical models and RA are controversial. In 
mice, systemic treatment with IL-11 reduced collagen induced arthritis (CIA) disease severity; 
conversely local injection of IL-11 exacerbated joint swelling [15, 16]. However, RA patients in 
remission had lower serum IL-11 levels that correlated with disease activity score (DAS)28 
improvement [17]. In phase I/II studies, treatment with IL-11 did not significantly modulate 
disease activity [18]. 
To address these controversies, we sought to elucidate the expression pattern, regulatory 
factors and the functional consequences of IL-11 and IL-11R expression in RA synovitis. We 
found that IL-11 and IL-11R are co-expressed in RA ST fibroblasts and endothelial cells and 
thus interconnect the function of these two cell types. Lining and sublining macrophages 
uniquely expressed IL-11; however because of IL-11Rabsence macrophages are not IL-11 
responder cells. The highest levels of IL-11 were secreted following IL-1 stimulation in RA ST 
fibroblasts compared to endothelial or RA myeloid cells activated by RA SF.  Direct binding of 
IL-11 to IL-11R on RA fibroblasts provoked cell migration, which was not detected when 
supernatants of IL-11 treated RA fibroblasts or endothelial cells were used. In contrast, the effect 
of IL-11 on angiogenesis was mediated both through its direct interaction with endothelial IL-
11R as well as indirectly via potent proangiogenic factors released from RA ST fibroblasts. 
Extending the in vitro results, IL-11 is strongly capable of forming new blood vessels in vivo in 
matrigel plugs. Our study suggests that IL-11 has a dual role in the pathogenesis of RA, both 
enhancing synovial fibroblast infiltration and further advancing disease severity by increasing 
the invasion of blood vessels into the RA pannus.    
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MATERIALS AND METHODS 
Patient Recruitment and Ethics 
Patients were recruited from the practices of orthopedic surgeons or rheumatologists in 
the group practice of the academic physicians of University of Illinois at Chicago. Synovial 
tissues and fibroblasts extracted from the synovium were obtained from individuals undergoing 
total joint replacement or synovectomy. All RA patients met the ACR 1987 Revised 
Classification of RA [19]. All studies were approved by the University of Illinois at Chicago 
Institutional Review Board and all donors provided written informed consent. All experiments 
were performed in accordance with these guidelines and regulation. STs from RA, OA and NLs 
were de-identified and were formalin fixed, paraffin-embedded and sectioned. Data recorded at 
the time of the tissue collection is date of collection and patient diagnosis. RA tissue samples or 
fluid submitted to our research required no special handling. RA peripheral blood was drawn into 
tubes containing citrate phosphate dextrose solution.   
RA patient population  
Blood was obtained from patients with RA, diagnosed according to the 1987 revised criteria of 
the American College of Rheumatology [19].  PB was obtained from 9 women and 1 man (mean 
age 57.1 ± 3.6 years). At the time of blood donation, patients were receiving no treatment (n=2), 
taking non-biological disease-modifying anti-rheumatic drug (DMARD)s (methotrexate, 
leflunomide,  sulfasalazine azathioprine) alone (n=4), or taking a TNF-α inhibitor with a 
DMARD (n=4). These studies were approved by the University of Illinois at Chicago 
Institutional Ethics Review Board and all donors gave informed written consent.   
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Antibodies and Immunohistochemical analysis 
STs were immunoperoxidase-stained using Vector Elite ABC kits (Vector Laboratories, 
Burlingame, CA), with diaminobenzidine (Vector Laboratories) as a chromogen. Briefly, slides 
were deparaffinized in xylene, followed by rehydration by transfer through graded alcohols. 
Antigens were unmasked by heat-induced retrieval in 10mM sodium citrate. STs were incubated 
with antibodies (Ab) to anti-human IL-11 (1:50; Santa Cruz biotechnology), anti-human IL-
11R (1:250; Santa Cruz biotechnology) or an IgG control. For co-localization or 
immunofluorescence studies, RA ST sections were stained with Abs to CD68 (1:100 Dako 
Cytomation, Carpinteria, CA), VWF (1:1000, Dako Cytomation) or Vimentin (1:2000, Thermo 
Fisher) to determine which cell types express IL-11 and IL-11R. Proteinase K (20µg/mL) was 
used as an additional antigen retrieval step for CD68 sections. Species specific AffiniPure 
F(ab’)2 antibodies conjugated to Alexa Fluor® 488 or Alexa Fluor® 594 (Jackson 
ImmunoResearch) were utilized as secondary antibodies. Immunofluorescence was imaged on a 
Nikon A1A confocal microscope and Nikon Elements Acquisition software. STs were scored for 
lining, sublining and endothelial cell staining by blinded observers (SJK and MVV) [20-22]. Cell 
staining was scored on a 0–5 scale; where 0=no staining, 1=few cells stained, 2=some (less than 
half) cells stained, 3= around half of the cells were stained positively 4= majority or more than 
half of the cells were positively stained and 5= all cells were positively stained. Scored data were 
pooled, and the mean ± SE was calculated in each data group [20-22]. 
Western blot analysis 
NL and RA peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll 
gradient (GE healthcare) thereafter macrophages were differentiated in vitro for 7 days as 
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described previously [23, 24]. Fibroblasts from fresh RA ST were isolated by mincing and 
digestion in a solution of dispase, collagenase, and DNase and the cells were used between 
passages 3 and 9 [20, 25]. In vitro differentiated NL and RA macrophages, human umbilical vein 
endothelial cells (HUVEC)s and RA ST fibroblasts were lysed and cell lysates were examined by 
Western blot analysis. Blots were probed with IL-11R (1:50, Santa Cruz Biotechnology) and 
actin was used as the equal loading control (1:1000, BD transduction laboratories).  
Cell treatment and ELISA 
IL-11 concentrations were quantified in NL plasma (n=35), OA plasma (n=35), RA 
plasma (n=40), OA SF (n=40) and RA SF (n=40) by ELISA (R&D Systems). To determine 
which cell types produce IL-11; RA ST fibroblasts, HUVECs, RA PB monocytes and RA in 
vitro differentiated macrophages were either untreated (PBS) or stimulated with 100ng/ml of 
TNF, IL-1, LPS, flagellin or IL-17 for 48h. In case of stimulation with 10% RA SF, IL-11 
concentration in the medium containing 10% RA SF was considered as 1 fold and IL-11 levels 
secreted from each cell type in response to 10% RA SF was demonstrated as fold increase. 
Additionally, protein levels of IL-8, VEGF, Ang-1, CXCL1, CXCL5 or bFGF  were quantified 
by ELISA (R&D Systems) in supernatants from RA ST fibroblasts or HUVECs that were 
untreated (PBS) or stimulated with IL-11 (100ng/ml) for 48h. Next, HUVECs and RA ST 
fibroblasts were stimulated with IL-11 (100ng/ml) for 48h and supernatants were analyzed for 
IL-6 and CCL2 secretion. 
RA ST fibroblast scratch assay  
A scratch was created in the middle of the wells that contained confluent RA ST 
fibroblasts [26]. Thereafter, RA ST fibroblasts (cultured in 5% FBS) were either untreated (PBS) 
 9 
 
or treated with IL-11 (1, 10, 100 and 200ng/ml; Gibco) or bFGF (+ control; 100ng/ml) for 24h. 
To determine the indirect effect of IL-11 on RA ST fibroblast migration; supernatants were 
obtained from 48h untreated (PBS sup) and IL-11 (100ng/ml) treated RA ST fibroblasts in the 
absence or presence of IL-11R-Fc chimera (added 1h prior to use) (R&D Systems, 10 g/ml; 
an antagonist to IL-11[27]). To test the impact of IL-11 treated endothelial cells on fibroblast 
migration, supernatants obtained from untreated HUVECs (PBS sup) or those treated with IL-11 
(100ng/ml) for 48h were assessed in fibroblast scratch assay in the absence or presence of 
soluble IL-11R-Fc chimera (10g/ml). In all scratch assay experiments, cells were fixed with 
10% formalin for 1h and were subsequently stained with 0.05% crystal violet for 1h prior to 
imaging. The number of cells in the scratch area was counted and compared to the untreated 
control. 
 
RA ST Fibroblasts Proliferation assay 
To determine the impact of IL-11 on RA ST fibroblast proliferation, MTT assay was 
performed. Cells were plated to 60-70% confluency in a 24 well plate and were either untreated 
(PBS) or treated with IL-11 (100ng/ml) or bFGF (+ control; 100ng/ml used only at 24h and 96h). 
Subsequent to 24h, 48h, 72h or 96h of treatment, MTT solution (5mg/ml) was added into each 
well for 3h. Thereafter, the MTT reaction was stopped [28] and the OD was determined at 570 
nm. The data in each time point is shown as fold increase above the counterpart control. 
Transwell endothelial cell migration assay 
  HUVEC transmigration was assessed using 8μm permeable inserts. To examine the effect 
of IL-11 on endothelial cell transmigration, PBS, IL-11 (1, 10, 100ng/ml) or VEGF (+ control; 
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100ng/ml) were added to the media (containing 0.5% BSA) in the wells of a 24 well plate and 
inserts containing endothelial cells (5105 cells/insert) were immersed in the media for 24h. 
Next, to establish that IL-11 induced endothelial cell transmigration is dependent on IL-11R, 
HUVECs placed in inserts, were tested for migration in response to IL-11 (100ng/ml) alone or 
IL-11 plus IL-11R-Fc chimera protein (10g/ml; added 1h prior to positioning the insert) for 
24h. To investigate whether factors released from RA ST fibroblasts can impact endothelial cell 
migration, supernatants from RA fibroblasts that were untreated (PBS sup) or treated with IL-11 
(100ng/ml) for 48h, were added to the wells in the absence or presence of IL-11R-Fc chimera 
protein (10g/ml) and endothelial cell migration was tested for 24h. Soluble IL-11R-Fc 
chimera protein was added to the IL-11 supernatants to negate the direct effect of IL-11 on 
endothelial migration. In all experiments following 24h incubation, inserts were removed, the 
non-migrating endothelial cells on the upper surface were detached with a cotton swab and the 
cells that migrated to the lower surface were fixed with 10% formalin for 1h. Thereafter, the 
migrated cells were stained with 0.05% crystal violet and imaged. The number of migrated cells, 
were counted in 3 different 10x fields in each treatment condition.  
Endothelial tube formation assay 
To determine the role of IL-11 in endothelial tube formation, HUVEC capillary 
formation was examined in response to IL-11 (1, 10, 100ng/ml) or VEGF (+ control; 100ng/ml) 
for 18h. Endothelial tube formation was also examined in the presence of IL-11 (100ng/ml) or 
RA SF (10%) with or without IL-11R-Fc chimera (10g/ml). To identify the proangiogenic 
factors released from IL-11 treated fibroblasts that are responsible for endothelial tube formation, 
HUVECs were pre-incubated with Abs against specific proangiogenic factor receptors, including 
 11 
 
anti-CXCR1 and anti-VEGFR2 (10g/ml; R&D systems), alone or in combination, for 1h prior 
to addition of supernatants obtained from IL-11 stimulated RA fibroblasts. In the same 
experiment, the direct effect of IL-11 was neutralized by pre-incubation with IL-11R-Fc 
chimera (10g/ml). The total number of tube branching points/4xfield was counted per well and 
the data represent average of 3 wells [29-31]. 
Matrigel plug assay in vivo 
To examine the effect of IL-11 on angiogenesis in vivo, we used a matrigel plug assay. C57BL/6 
mice were injected subcutaneously with 500μl matrigel containing PBS or bFGF (100ng) as 
negative or positive control and mouse IL-11 (4μg) served as the experimental condition. After 
10 days, mice were sacrificed; matrigel plugs were removed and analyzed for vascular density. 
Histology slides from different treatment groups were examined by H&E staining. Vascular 
density was scored on a 0-5 scale, where 0 = no tubules, 1= few tubules, 2 = more dense tubules, 
3= tubules with multilayer walls, 4= tubules with multilayer walls and red blood cells and 5= 
tubules with multilayer walls and connective tissues. 
Data Sharing Plan 
Materials generated under this project will be disseminated in accordance with the 
policies of the University of Illinois at Chicago and NIH. The results, techniques and the 
protocol generated in this study will be made available after being accepted for publication by 
depositing to Pubmed Central.  
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Statistical Analysis 
One way analysis of variance was used for comparisons among multiple groups, followed 
by Student’s post hoc 2-tailed T-test. Students paired and unpaired 2-tailed test were used for 
comparisons between 2 groups. P values less than 0.05 were considered significant. 
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RESULTS 
Elevated levels of IL-11 and IL-11R are detected in RA specimen 
To understand the role of IL-11 in RA, we investigated the expression pattern of IL-11 
and IL-11R in RA compared to OA and NL specimens. We found that expression of IL-11 was 
significantly elevated (2 fold) in the lining layer macrophages and fibroblasts as well as in the 
sublining macrophages and endothelial cells of RA relative to NL STs (Figs. 1A-B). In OA STs, 
IL-11 expression levels were lower (2.5 fold) in the lining cells and sublining macrophages 
compared to RA STs (Figs. 1A-B). Serial section and immunofluorescence staining of IL-11, 
CD68, VWF and vimentin in RA STs indicated that IL-11 is expressed by lining RA fibroblasts 
and macrophages in addition to sublining endothelial cells, macrophages and a number of 
fibroblasts (Figs. 1D-E). In agreement with these findings, IL-11 levels were significantly 
enhanced in RA SF compared to OA SF (47 fold) and plasma from RA (19 fold), OA (75 fold) 
and NL (18 fold) individuals (Fig. 1C). Similar to IL-11, IL-11R expression was markedly 
elevated in RA compared to NL ST lining fibroblasts (2.5 fold), sublining endothelial cells (2 
fold) and fibroblasts (Figs. 2A-B). In contrast, IL-11R was absent in RA ST sublining and 
lining macrophages (Figs. 2C-E). Corroborating the histological studies, Western blot analysis 
authenticated that while IL-11R is expressed in endothelial cells (as shown in HUVECs) and 
RA ST fibroblasts, it is absent in NL and RA macrophages (Figs. 2A-E). The expression pattern 
of IL-11R indicates that fibroblasts and endothelial cells are the primary responders to IL-11 in 
RA ST.   
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IL-11 is produced from RA ST fibroblasts, endothelial cells, RA monocytes and macrophages 
Next, different cell types were examined to determine the potential sources of IL-11 
production. Consistent with the histology, RA ST fibroblasts secreted markedly higher levels of 
IL-11 upon stimulation with IL-1 (51 fold) and RA SF (6.5 fold; 42 vs 285 pg/ml) compared to 
the control treatment group (Figs. 3A, 3E). IL-11 was produced in endothelial cells (2.5 fold; 42 
vs 105 pg/ml), RA PB monocytes (5.5 fold; 42 vs 236) and RA PB in vitro differentiated 
macrophages (3 fold; 42 vs 121) following RA SF stimulation (Fig. 3E). In contrast, endothelial 
cells, RA monocytes and RA in vitro differentiated macrophages were unable to secrete IL-11 in 
response to a number of proinflammatory factors including ligands to TLRs (Figs. 3B-D).  
Since hypoxia is an important mechanism that stimulates production of pro-angiogenic 
factors, RA myeloid cells and endothelial cells were exposed to hypoxia as well as IL-6 
stimulation for 48h. Results from these studies also demonstrate that hypoxia was not capable of 
instigating secretion of IL-11 from RA macrophages or HUVECs. Likewise, IL-6 did not impact 
IL-11 release from RA macrophages or HUVECs under normoxia or hypoxia. In contrast the 
positive control, RA SF, markedly enhanced secretion of IL-11 from RA macrophages and 
HUVECs and the reduced oxygen level in hypoxic condition did not affect this process. 
Alternatively, there may be a combination of multiple factors present in RA SF that is 
responsible for IL-11 production from endothelial and RA myeloid cells. Given that the highest 
concentration of IL-11 secretion was induced in RA ST fibroblasts by IL-1, the proliferating 
fibroblasts within the pannus may be an important source for IL-11 production.     
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Binding of IL-11 to IL-11R expressed on RA fibroblasts promotes cell migration but not cell 
proliferation 
We found that expression of IL-11 and IL-11R is markedly enhanced in RA ST 
fibroblasts (Figs. 1D-E, 2D-E). Since fibroblast migration and hyperplasia contribute to pannus 
formation [32, 33], the impact of IL-11 and its receptor was examined in model systems relevant 
to these aspects of RA. Employing a scratch assay, we observed that IL-11 could dose 
dependently elevate RA fibroblast migration starting at 100ng/ml (Fig. 4A). The effect of IL-11 
on RA fibroblast migration was abrogated when soluble IL-11R-Fc chimeric protein was 
utilized (Figs. 4B-C). In contrast, the supernatants obtained from IL-11 stimulated RA fibroblasts 
or HUVECs were unable to promote RA fibroblast migration (Figs. 4B-E). When the impact of 
IL-11 on RA ST fibroblast proliferation was evaluated, we found that while this manifestation 
was unaffected by IL-11 therapy, it was markedly accelerated by bFGF treatment (Fig. 4F). 
These findings suggest that IL-11 binding to IL-11R expressed on RA ST fibroblast directly 
provokes cell migration, and an indirect pathway is not involved in this process.  
 
IL-11 contributes to endothelial cell migration and tube formation via both direct and indirect 
mechanisms  
Angiogenesis is indispensable for initiation and progression of RA inflammation and 
bone destruction [34]. Since IL-11 and IL-11R were upregulated in RA ST vascular 
endothelium, we next investigated the impact of IL-11 on proangiogenic factors, endothelial 
transmigration and tube formation. HUVECs activated with IL-11 were screened for production 
of proangiogenic factors such as Ang-1, VEGF, FGF, CXCL1 and CXCL5. Results from these 
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experiments demonstrated that HUVECs were only capable of producing modest levels of Ang-1 
(22% increase) in response to IL-11 stimulation (Fig. 5A). IL-11 induced endothelial cell 
migration (3-15 fold) and tube formation (2-3 fold) in a dose dependent manner, starting at a low 
concentration of 1 ng/ml (Figs. 5B, 5E-F). This indicates that IL-11 (up to 3.7 ng/ml is expressed 
in RA SF) can contribute to angiogenesis at a physiologically relevant concentration. Endothelial 
transwell migration was significantly impaired in the presence of soluble IL-11R-Fc chimeric 
protein (50%), confirming that the migratory effect of IL-11 is modulated via endothelial IL-
11R binding (Figs. 5C-D). Corroborating these findings, we found that ligation of SF IL-11 to 
endothelial IL-11Rwas involved in RA angiogenesis, as addition of soluble IL-11R-Fc 
chimeric protein significantly suppressed SF induced tube formation (Fig. 5G). 
As RA fibroblasts secrete IL-8 and VEGF but not Ang1, CXCL1 or CXCL5 in response 
to IL-11 (Fig. 6A), we next explored whether these proangiogenic factors contribute to IL-11 
induced angiogenesis. We found that supernatants from IL-11 treated RA fibroblasts facilitate 
endothelial cell transwell migration that was not affected by addition of soluble IL-11R-Fc 
chimeric protein (Figs. 6B-C), indicating that this process may be due to IL-8 and VEGF but not 
IL-11. We observed that endothelial tube formation was suppressed by neutralizing Abs to 
CXCR1 (IL-8 receptor alpha) and VEGFR2 (VEGF receptor)(Figs. 6D-E).  
Interestingly, HUVECs (IL-6) and RA ST fibroblasts (IL-6 and CCL2) secrete 2 fold 
higher levels of IL-6 and/or CCL2 in response to IL-11 activation (Fig. 6F). Although 
macrophages are nonresponsive to IL-11 stimulation due to absence of IL-11Rα on these cells, 
we anticipate that IL-11 can indirectly influence RA macrophage activation or migration via IL-6 
and CCL2 production from endothelial cells and RA ST fibroblasts.  
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Taken together, we conclude that IL-11 directly promotes angiogenesis at concentrations 
present in RA joint; IL-11 can further amplify this effect by triggering the infiltrating fibroblasts 
to secrete potent proangiogenic factors.  
IL-11 induces angiogenesis in vivo in matrigel plugs 
The role of IL-11 on angiogenesis in vivo was assessed by determining its effect on blood vessel 
formation in matrigel plugs. Matrigel blood vessel formation was examined histologically by 
H&E staining following 10 days of inoculation. The histological analysis demonstrated that IL-
11 markedly potentiates formation of blood vessel capillaries, increasing the vessel density by 2 
fold compared to the control group (Figs. 7A-B). We observed red blood cell deposition in 
matrigel plugs containing bFGF, however these cells were absent in those containing IL-11. 
These results support the role of IL-11 in angiogenesis in vivo. 
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DISCUSSION 
To date, the unique roles of IL-11 in RA have not been defined. In this study we focused 
on uncovering the expression pattern of IL-11 and IL-11R in RA, and elucidating how their 
interaction regulates disease pathology. We determined that IL-11, released from RA ST 
fibroblasts and other cells, can bind to its receptor on fibroblasts to exert trafficking, without 
affecting cell proliferation. IL-11 also provokes the infiltrating RA ST fibroblasts to produce 
elevated levels of VEGF and IL-8 that promote joint angiogenesis. Moreover, at physiological 
concentrations, IL-11 induces formation of new blood vessels in vitro and in vivo in matrigel 
plugs, which can further potentiate neovascularization in the RA pannus (Fig. 7C).  
Interestingly, a variety of mesenchymal cell types express IL-11, which include 
fibroblasts in connective tissues, lungs, uterus, osteosarcoma cell lines and osteoblasts [5]. In the 
majority of these cell types, IL-11 gene expression is regulated by IL-1and phorbol myristate 
acetate (PMA) through induced mRNA stability [5]. Previous studies show that freshly isolated 
RA synoviocytes spontaneously produce IL-11 which is blunted by indomethacin, 
dexamethasone and IL-4 treatment [35, 36]. The same group of investigators found that IL-1 
and TNF can synergistically promote IL-11 production from RA ST fibroblasts through a 
mechanism that is dependent on prostaglandin E2 (PGE2). IFN- inhibited IL-1 induced 
secretion of IL-11 from cultured RA fibroblasts, but not fresh RA synovial cells [35, 37].  
Extending these observations, we document that IL-11 and IL-11R are co-localized in 
RA ST fibroblasts and that IL-11 production is regulated by IL-1. We further observed that RA 
ST endothelial cells express IL-11 and are highly responsive to this cytokine due to expression of 
IL-11R. RA PB or ST macrophages do not express IL-11R and are therefore unresponsive to 
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IL-11, despite myeloid cell production of IL-11 in response to RA SF. Others have shown that 
when macrophages and RA fibroblasts were isolated from fresh RA STs, spontaneous IL-11 was 
released from both cell types [38]. Our results indicate that while RA fibroblasts and endothelial 
cells are producers and responders to IL-11, RA macrophages are mainly producers of this 
factor. 
We found that RA SF was the common stimulus that was capable of potentiating IL-11 
secretion from RA ST fibroblasts, endothelial cells and RA myeloid cells; this may be in part due 
to the combined effect of multiple factors. In contrast to an earlier observation that demonstrates 
that SF from RA and OA have comparable levels of IL-11 [38], we document that IL-11 levels 
are significantly higher in RA SF compared to OA SF and plasma as well as RA and NL plasma. 
However, all previous studies are in agreement that IL-11 concentration is markedly increased in 
RA SF compared to RA serum, while IL-11 levels are even higher in RA ST relative to RA SF 
[38-40].  Interestingly, when compared to other potent proangiogenic factors expressed in RA 
patients, SF levels of IL-11 were higher than VEGF and comparable to bFGF, whereas IL-11’s 
concentration was lower than those reported for CXCL1 and CXCL5 [41-43]. 
The evidence regarding role of IL-11 in RA has been conflicting, since both pro- and 
anti-inflammatory effects have been reported in different cell types and preclinical models.  
When mouse bone marrow cells were co-cultured with cells extracted from calvaria, IL-11 
together with parathyroid hormone significantly increased osteoclast maturation and pit 
formation [44]. Consistent with a role of IL-11 in bone erosion, IL-11 differentiated TH-17 cells 
independently of IL-6. However, IL-11 also synergizes with IL-6, IL-1 and IL-23 in amplifying 
TH-17 cell polarization [14]. Additionally, in in vitro and in vivo studies, IL-11 augmented  
antigen-specific Ab production from plasma cells, although this effect was felt to be indirect, 
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through actions of IL-11 on CD4+ T cells and/or antigen-presenting cells [45]. Substantiating the 
pathogenic role of IL-11 in RA, we document that the density of the newly formed capillary 
tubules is 2 fold higher in the matrigel plugs containing IL-11 compared to the control plugs. 
In contrast, several studies have documented the anti-inflammatory effect of IL-11. It is 
shown that in LPS treated mice as well as in thioglycollate elicited peritoneal macrophages; 
pretreatment with IL-11 impairs LPS induced TNF and IL-1 production by suppressing NF-B 
signaling [46, 47]. Supporting these observations, anti-IL-11 Ab therapy alone or in combination 
with anti-IL-10 Ab increased TNF production from 2 to 22 fold in RA synovial membrane cells, 
suggesting that endogenous IL-11 and IL-10 can synergistically abrogate TNF production [40]. 
Interestingly, in the RA synovial membrane, IL-11 treatment had no effect on spontaneous TNF 
production; and these investigators document that the anti-inflammatory effect of IL-11 is only 
mediated in presence of its soluble receptor [40]. The fact that some cells including macrophages 
respond to IL-11 only in presence of soluble IL-11R is consistent with our finding that NL and 
RA macrophages do not express IL-11R. The lack of effect on macrophages limits the 
therapeutic use of IL-11 as an anti-inflammatory agent. The limited activity of IL-11, in the 
absence of its soluble receptor, may justify why IL-11 administration did not significantly 
ameliorate RA patients based on an American College of Rheumatology (ACR) 20% response 
[18].         
Although numerous groups have reported that IL-11 is secreted from RA ST fibroblasts, 
the mechanism of IL-11 function is unclear in RA. We show for the first time that IL-11 plays an 
important role in migration of RA ST fibroblasts that is mediated through binding of IL-11 to its 
receptor. Factors released from IL-11 activated RA ST fibroblasts or endothelial cells do not 
promote fibroblast migration, however these cells secrete factors such as IL-6 and CCL2 that 
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may play a role in myeloid cell activation or infiltration. It was previously shown that arthritis 
induced by local injection of IL-1 is alleviated in IL-11R-/- mice or with use of neutralizing IL-
11 Ab, suggesting that IL-1 driven arthritis is in part due to IL-11 induction [16]. These 
observations are in agreement with our findings that demonstrate that IL-1 enhanced production 
of IL-11 from RA ST fibroblasts is  responsible for fibroblast trafficking.  
Similar to IL-11, other pro-inflammatory factors including IL-17 as well as TH-17 
associated cytokines IL-21 and IL-22, TNF, LPS, CCL2, CXCL10, CXCL12 and CX3CL1 
provoke RA ST fibroblast migration [48-54]. However, unlike IL-1 that modulates RA fibroblast 
migration via IL-11 induction and binding of IL-11 to the IL-11R, other monokines such as 
TNF, CCL2, CXCL10 and CXCL12 can facilitate this process by engagement of chemokine 
receptors distinct from IL-11R [54]. Also, the inflammatory monokines mechanism of action is 
partially different from IL-11, as they trigger both migration and proliferation of fibroblasts, 
whereas IL-11 exclusively facilitates RA fibroblast trafficking [48-54].    
We uncover for the first time that IL-11 plays a novel role in RA angiogenesis, as 
blockade of its signaling impacts RA SF induced capillary tube formation. We show that IL-11-
activated RA ST fibroblasts release physiological levels of VEGF and IL-8 that further augment 
the direct effect of IL-11 on angiogenesis. We conclude that IL-11 therefore represents a novel 
connection between the synovial fibroblasts and the new invading blood vessels in the RA joint, 
adding a new dimension to our current understanding [55] of how RA synovial fibroblasts can 
deliver proangiogenic signals to synovial endothelial cells.   
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FIGURE LEGENDS 
Fig. 1 IL-11 is overexpressed in RA ST lining fibroblasts and macrophages as well as 
sublining endothelial cells and macrophages and its level in RA SF is significantly higher 
than OA SF and plasma from RA, OA and NL individuals. A. STs from NL, OA and RA 
were stained with anti-IL-11 Ab (original magnification x 200) and (B) staining was scored on a 
scale of 0-5 in the lining, sublining and endothelial cells, n=8-9. C. IL-11 protein concentration 
was determined in RA SF (n=40) and OA SF (n=40) as well as in plasma from RA (n=40), OA 
(n=35) and NL (n=35) individuals. D. RA ST serial sections were stained with Abs to anti-IL-11, 
CD68, VWF or Vimentin to establish which cell types produce IL-11, n=5. E. To confirm serial 
section studies, individual (red or green) as well as the overlapping (yellow) 
immunofluorescence staining was shown of RA STs that were stained with Abs to anti-IL-11 
(green) or cell markers per slide including CD68 (red), VWF (red) or Vimentin (red) (original 
magnification x 400), n=5.  Values are the mean ± SE. * represents p <0.05.   
 
Fig. 2 IL-11R expression is markedly higher in ST lining fibroblasts and sublining 
fibroblasts and endothelial cells of RA compared to NL ST. A. STs from NL, OA and RA 
were stained with anti-IL-11R Ab (original magnification x 200) and (B) staining was scored 
on a scale of 0-5 in the lining, sublining and endothelial cells, n=8-9. C. The IL-11R expression 
was quantified in NL and RA PB in vitro differentiated macrophages (Ms), RA ST fibroblasts 
and HUVECs by Western blot analysis using anti-IL-11R Ab, n=5. D. RA ST serial sections 
were stained with Abs to anti-IL-11R, CD68, VWF or Vimentin to establish which cell types 
express IL-11R, n=5. E. To confirm serial section studies, individual (red or green) as well as 
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the overlapping (yellow) immunofluorescence staining was shown of RA STs that were stained 
with Abs to anti-IL-11R (green) or cell markers per slide including CD68 (red), VWF (red) or 
Vimentin (red) (original magnification x 400), n=5. Values are the mean ± SE. * represents p 
<0.05.   
 
Fig. 3 Production of IL-11 was detected in RA ST fibroblasts, endothelial cells, RA PB 
monocytes and macrophages following stimulation. RA fibroblasts (A), HUVECs (B), RA PB 
monocytes (C) and RA in vitro differentiated macrophages (Ms)(D) were untreated (PBS) or 
stimulated with 100 ng/ml of TNF, IL-1, LPS and Flagellin (Flag), IL-17 for 48h. Supernatants 
were tested for IL-11 protein concentration by ELISA, n=6. E. RA fibroblasts, HUVECs, RA PB 
monocytes, and RA Ms were stimulated with 10% RA SF for 48h. IL-11 concentration in the 
medium containing 10% RA SF was considered as 1 fold and IL-11 levels secreted from each 
cell type in response to 10% RA SF was demonstrated as fold increase above medium containing 
10% RA SF. Values are the mean ± SD. * represents p <0.05.   
 
Fig. 4 Ligation of IL-11 to IL-11R induces RA ST fibroblasts migration. A. Effect of IL-11 
(1-200ng/ml) on RA ST fibroblast migration was examined using an in vitro scratch assay for 
24h. B. Representative images of RA ST fibroblast scratch assays performed on untreated cells 
(PBS) or cells treated with IL-11 (100ng/ml) with or without IL-11R-Fc chimera (10g/ml, IL-
11 antagonist). Additionally, supernatants obtained from RA ST fibroblasts that were untreated 
(PBS sup) or stimulated for 48h with IL-11 (100ng/ml) were tested in presence or absence of IL-
11R-Fc chimera (10g/ml). C. Number of fibroblasts counted in the scratch area shown in B. 
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D. Representative images of the RA fibroblast scratch assay performed for 24h using the 
supernatants from HUVECs that were untreated (PBS sup) or treated with IL-11 (100ng/ml) in 
the absence or presence of IL-11R-Fc chimera (added 1h prior to use). E. Number of 
fibroblasts counted in the scratch area shown in D. F. MTT assay was performed in RA ST 
fibroblasts that were untreated (PBS) or treated with 100ng/ml of IL-11 or bFGF for 24-96h. OD 
was measured at 570 nm and the data in each time point is shown as fold increase above control. 
In all the experiments, bFGF (100ng/ml) was used as a positive control. All treatments were 
done in triplicate and each experiment was performed 3 independent times. Values are the mean 
± SD. * represents p <0.05.   
 
Fig. 5 IL-11 promotes endothelial cell migration and tube formation that is mediated 
through IL-11R ligation. A. Protein levels of Ang-1, VEGF, bFGF, CXCL1, CXCL5 and IL-8 
were quantified in supernatants obtained from HUVECs stimulated with PBS or IL-11 
(100ng/ml) for 48h, n=5. B. Effect of IL-11 (1-100ng/ml) was determined on HUVEC migration 
using inserts of 8m following 24h incubation. C. Representative images from HUVEC 
migration in response to IL-11 (100ng/ml) alone or IL-11 plus IL-11R-Fc chimera (10g/ml). 
D. Number of endothelial cells that migrated in response to different treatment conditions shown 
in C. E. IL-11 (1-100ng/ml) effect was examined on HUVECs (25,000 cells/well) tube formation 
following 18h. The number of branching points were counted in each treatment and compared to 
negative control (PBS, 1% FBS in medium). F. Representative images of tube formation when 
HUVECs were treated with IL-11 (100ng/ml) or RA SF (10%) in absence or presence of IL-
11R-Fc chimera (10g/ml). G. The number of branching points formed in different treatment 
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groups shown in F. In all experiments, VEGF (100ng/ml) was regarded as positive control. 
Experiments were performed in triplicates and repeated six times. Values are the mean ± SD. * 
represents p <0.05.   
 
Fig. 6 VEGF and IL-8 produced from IL-11 treated RA ST fibroblasts, contribute to the 
indirect effect of IL-11 on angiogenesis. A. RA ST fibroblasts were either untreated (PBS) or 
stimulated with IL-11 (100ng/ml) for 48h and concentration of IL-8, VEGF, Ang1, CXCL1 and 
CXCL5 was determined by ELISA. B. Representative images of HUVECs that migrated in 
response to supernatants from RA ST fibroblasts that were untreated (PBS sup) or treated for 48h 
with IL-11 (100ng/ml). IL-11R-Fc chimera (10g/ml) was incubated for 1h with the collected 
supernatants. C. Number of the HUVECs that migrated in different treatment groups shown in B.  
D. Endothelial tube formation assay was performed (18h) in response to supernatants from RA 
ST fibroblasts that were untreated (PBS sup) or treated with IL-11 (100ng/ml) for 48h, while 
HUVECs were preincubated with 10g/ml of IgG, anti-CXCR1, anti-VEGFR2, anti-CXCR1 
plus anti-VEGFR2 Abs. All the experiments were performed in triplicate and repeated three 
times, n=3. E. The branching points were counted in each treatment condition in D. F. RA PB in 
vitro differentiated macrophages were untreated (PBS) or stimulated with IL-11 (100ng/ml) for 
48h and the supernatant levels of IL-6 and CCL2 were determined by ELISA, n=5. Values are 
the mean ± SD. * represents p <0.05.   
Fig. 7 IL-11 promotes formation of new blood vessels in matrigel plug in vivo.  A. C57BL/6 
mice were injected subcutaneously with 500μl matrigel containing PBS (-control), IL-11 (4μg) 
or bFGF (100ng; +control), n=5 mice per treatment group. After 10 days of inoculation, mice 
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were sacrificed; matrigel plugs were removed and analyzed for vascular density. B. Histology 
slides from different treatment groups were examined by H&E staining and scored on a 0-5 
scale, n=5. C. Schematic figure showing the mechanism of IL-11 function in RA. Values are the 
mean ± SE. * represents p <0.05.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 27 
 
ACKNOWLEGEMENTS: 
This work was supported in part by awards from Department of Veteran’s Affairs MERIT 
Award 1I01BX002286, the National Institutes of Health AR056099 and AR065778, funding 
provided by Department of Defense PR093477. We would like to acknowledge Dr. Rhonda 
Kineman for critically reviewing the paper and granting us access to use her laboratory 
microscope.   
 
COMPETING INTERESTS: 
None declared. 
 
AUTHORS CONTRIBUTION: 
Designed the research: HAE, SS 
Performed the research: HAE, MVV, ABE, ZC, SJK, KV, KP, SS 
Analyzed the data: HAE, ZC, MVV, KV, MK, HMA, SJK, IBM, DAF, SS   
Provided reagents: SA, GZ  
Writing the paper: All the authors contributed to writing the paper. 
 
 
 
 28 
 
LITERATURE CITED 
1. Heinrich, P. C., I. Behrmann, S. Haan et al (2003) Principles of interleukin (IL)-6-type 
cytokine signalling and its regulation. Biochem. J. 374:1-20. 
2. Putoczki, T. L., S. Thiem, A. Loving et al (2013) Interleukin-11 is the dominant IL-6 
family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. 
Cancer Cell 24:257-271. 
3. Paul, S. R., F. Bennett, J. A. Calvetti et al (1990) Molecular cloning of a cDNA encoding 
interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc. 
Natl. Acad. Sci. U. S. A. 87:7512-7516. 
4. Paul, S. R., Y. C. Yang, R. E. Donahue et al (1991) Stromal cell-associated 
hematopoiesis: immortalization and characterization of a primate bone marrow-derived 
stromal cell line. Blood 77:1723-1733. 
5. Du, X., and D. A. Williams (1997) Interleukin-11: review of molecular, cell biology, and 
clinical use. Blood 89:3897-3908. 
6. Xu, D. H., Z. Zhu, M. R. Wakefield et al (2016) The role of IL-11 in immunity and 
cancer. Cancer Lett. 373:156-163. 
7. Quesniaux, V. F., S. C. Clark, K. Turner et al (1992) Interleukin-11 stimulates multiple 
phases of erythropoiesis in vitro. Blood 80:1218-1223. 
8. Jacobsen, S. E., C. Okkenhaug, O. P. Veiby et al (1994) Interleukin 13: novel role in 
direct regulation of proliferation and differentiation of primitive hematopoietic progenitor 
cells. J. Exp. Med. 180:75-82. 
 29 
 
9. Orazi, A., R. J. Cooper, J. Tong et al (1996) Effects of recombinant human interleukin-11 
(Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow. Exp. 
Hematol. 24:1289-1297. 
10. Putoczki, T., and M. Ernst (2010) More than a sidekick: the IL-6 family cytokine IL-11 
links inflammation to cancer. J. Leukoc. Biol. 88:1109-1117. 
11. Taniguchi, K., and M. Karin (2014) IL-6 and related cytokines as the critical lynchpins 
between inflammation and cancer. Semin. Immunol. 26:54-74. 
12. Yoshizaki, A., T. Nakayama, K. Yamazumi et al (2006) Expression of interleukin (IL)-11 
and IL-11 receptor in human colorectal adenocarcinoma: IL-11 up-regulation of the 
invasive and proliferative activity of human colorectal carcinoma cells. Int. J. Oncol. 
29:869-876. 
13. Yamazumi, K., T. Nakayama, T. Kusaba et al (2006) Expression of interleukin-11 and 
interleukin-11 receptor alpha in human colorectal adenocarcinoma; 
immunohistochemical analyses and correlation with clinicopathological factors. World J. 
Gastroenterol. 12:317-321. 
14. Zhang, X., Y. Tao, M. Chopra et al (2015) IL-11 Induces Th17 Cell Responses in 
Patients with Early Relapsing-Remitting Multiple Sclerosis. J. Immunol. 194:5139-5149. 
15. Walmsley, M., D. M. Butler, L. Marinova-Mutafchieva et al (1998) An anti-
inflammatory role for interleukin-11 in established murine collagen-induced arthritis. 
Immunology 95:31-37. 
16. Wong, P. K., I. K. Campbell, L. Robb et al (2005) Endogenous IL-11 is pro-
inflammatory in acute methylated bovine serum albumin/interleukin-1-induced 
(mBSA/IL-1)arthritis. Cytokine 29:72-76. 
 30 
 
17. Chung, S. J., Y. J. Kwon, M. C. Park et al (2011) The correlation between increased 
serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid 
arthritis patients. Yonsei Med. J. 52:113-120. 
18. Moreland, L., R. Gugliotti, K. King et al (2001) Results of a phase-I/II randomized, 
masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the 
treatment of subjects with active rheumatoid arthritis. Arthritis Res. 3:247-252. 
19. Arnett, F. C., S. M. Edworthy, D. A. Bloch et al (1988) The American Rheumatism 
Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis 
Rheum. 31:315-324. 
20. Pickens, S. R., N. D. Chamberlain, M. V. Volin et al (2011) Characterization of CCL19 
and CCL21 in rheumatoid arthritis. Arthritis Rheum. 63:914-922. 
21. Pickens, S. R., N. D. Chamberlain, M. V. Volin et al (2011) Characterization of 
interleukin-7 and interleukin-7 receptor in the pathogenesis of rheumatoid arthritis. 
Arthritis Rheum. 63:2884-2893. 
22. Chamberlain, N. D., O. M. Vila, M. V. Volin et al (2012) TLR5, a novel and unidentified 
inflammatory mediator in rheumatoid arthritis that correlates with disease activity score 
and joint TNF-alpha levels. J. Immunol. 189:475-483. 
23. Kim, S. J., Z. Chen, A. B. Essani et al (2015) Identification of a novel TLR7 endogenous 
ligand in RA synovial fluid that can provoke arthritic joint inflammation. Arthritis 
Rheumatol. 
24. Chen, Z., S. J. Kim, N. D. Chamberlain et al (2013) The novel role of IL-7 ligation to IL-
7 receptor in myeloid cells of rheumatoid arthritis and collagen-induced arthritis. J. 
Immunol. 190:5256-5266. 
 31 
 
25. Shahrara, S., S. R. Pickens, A. M. Mandelin, 2nd et al (2010) IL-17-mediated monocyte 
migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant 
protein-1 induction. J. Immunol. 184:4479-4487. 
26. Morgan, R., J. Endres, N. Behbahani-Nejad et al (2015) Expression and function of 
aminopeptidase N/CD13 produced by fibroblast-like synoviocytes in rheumatoid arthritis: 
role of CD13 in chemotaxis of cytokine-activated T cells independent of enzymatic 
activity. Arthritis Rheumatol 67:74-85. 
27. Curtis, D. J., D. J. Hilton, B. Roberts et al (1997) Recombinant soluble interleukin-11 
(IL-11) receptor alpha-chain can act as an IL-11 antagonist. Blood 90:4403-4412. 
28. Ota, F., A. Maeshima, S. Yamashita et al (2003) Activin A induces cell proliferation of 
fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Rheum. 48:2442-2449. 
29. Pickens, S. R., M. V. Volin, A. M. Mandelin, 2nd et al (2010) IL-17 contributes to 
angiogenesis in rheumatoid arthritis. J. Immunol. 184:3233-3241. 
30. Pickens, S. R., N. D. Chamberlain, M. V. Volin et al (2012) Role of the CCL21 and 
CCR7 pathways in rheumatoid arthritis angiogenesis. Arthritis Rheum. 64:2471-2481. 
31. Chen, Z., S. J. Kim, A. B. Essani et al (2015) Characterising the expression and function 
of CCL28 and its corresponding receptor, CCR10, in RA pathogenesis. Ann. Rheum. Dis. 
74:1898-1906. 
32. Lefevre, S., A. Knedla, C. Tennie et al (2009) Synovial fibroblasts spread rheumatoid 
arthritis to unaffected joints. Nat. Med. 15:1414-1420. 
33. Bartok, B., and G. S. Firestein (2010) Fibroblast-like synoviocytes: key effector cells in 
rheumatoid arthritis. Immunol. Rev. 233:233-255. 
 32 
 
34. Elshabrawy, H. A., Z. Chen, M. V. Volin et al (2015) The pathogenic role of 
angiogenesis in rheumatoid arthritis. Angiogenesis 18:433-448. 
35. Taki, H., E. Sugiyama, T. Mino et al (1998) Differential inhibitory effects of 
indomethacin, dexamethasone, and interferon-gamma (IFN-gamma) on IL-11 production 
by rheumatoid synovial cells. Clin. Exp. Immunol. 112:133-138. 
36. Taki, H., E. Sugiyama, A. Kuroda et al (2000) Interleukin-4 inhibits interleukin-11 
production by rheumatoid synovial cells. Rheumatology (Oxford) 39:728-731. 
37. Mino, T., E. Sugiyama, H. Taki et al (1998) Interleukin-1alpha and tumor necrosis factor 
alpha synergistically stimulate prostaglandin E2-dependent production of interleukin-11 
in rheumatoid synovial fibroblasts. Arthritis Rheum. 41:2004-2013. 
38. Okamoto, H., M. Yamamura, Y. Morita et al (1997) The synovial expression and serum 
levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in 
rheumatoid arthritis. Arthritis Rheum. 40:1096-1105. 
39. Trontzas, P., E. F. Kamper, A. Potamianou et al (1998) Comparative study of serum and 
synovial fluid interleukin-11 levels in patients with various arthritides. Clin. Biochem. 
31:673-679. 
40. Hermann, J. A., M. A. Hall, R. N. Maini et al (1998) Important immunoregulatory role of 
interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum. 
41:1388-1397. 
41. Yamashita, A., Y. Yonemitsu, S. Okano et al (2002) Fibroblast growth factor-2 
determines severity of joint disease in adjuvant-induced arthritis in rats. J. Immunol. 
168:450-457. 
 33 
 
42. Koch, A. E., S. L. Kunkel, M. R. Shah et al (1995) Growth-related gene product alpha. A 
chemotactic cytokine for neutrophils in rheumatoid arthritis. J. Immunol. 155:3660-3666. 
43. Koch, A. E., S. L. Kunkel, L. A. Harlow et al (1994) Epithelial neutrophil activating 
peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J. Clin. Invest. 
94:1012-1018. 
44. Girasole, G., G. Passeri, R. L. Jilka et al (1994) Interleukin-11: a new cytokine critical for 
osteoclast development. J. Clin. Invest. 93:1516-1524. 
45. Yin, T. G., P. Schendel, and Y. C. Yang (1992) Enhancement of in vitro and in vivo 
antigen-specific antibody responses by interleukin 11. J. Exp. Med. 175:211-216. 
46. Trepicchio, W. L., M. Bozza, G. Pedneault et al (1996) Recombinant human IL-11 
attenuates the inflammatory response through down-regulation of proinflammatory 
cytokine release and nitric oxide production. J. Immunol. 157:3627-3634. 
47. Trepicchio, W. L., L. Wang, M. Bozza et al (1997) IL-11 regulates macrophage effector 
function through the inhibition of nuclear factor-kappaB. J. Immunol. 159:5661-5670. 
48. Lee, S. Y., S. K. Kwok, H. J. Son et al (2013) IL-17-mediated Bcl-2 expression regulates 
survival of fibroblast-like synoviocytes in rheumatoid arthritis through STAT3 activation. 
Arthritis Res. Ther. 15:R31. 
49. Xing, R., L. Yang, Y. Jin et al (2016) Interleukin-21 Induces Proliferation and 
Proinflammatory Cytokine Profile of Fibroblast-like Synoviocytes of Patients with 
Rheumatoid Arthritis. Scand. J. Immunol. 83:64-71. 
50. Zhu, J., E. Jia, Y. Zhou et al (2015) Interleukin-22 Secreted by NKp44+ Natural Killer 
Cells Promotes Proliferation of Fibroblast-Like Synoviocytes in Rheumatoid Arthritis. 
Medicine (Baltimore) 94:e2137. 
 34 
 
51. Calmon-Hamaty, F., B. Combe, M. Hahne et al (2011) Lymphotoxin alpha stimulates 
proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial 
fibroblasts. Cytokine 53:207-214. 
52. Elias, J. A., T. Zheng, N. L. Whiting et al (1994) IL-1 and transforming growth factor-
beta regulation of fibroblast-derived IL-11. J. Immunol. 152:2421-2429. 
53. Guo, X., Y. Pan, C. Xiao et al (2012) Fractalkine stimulates cell growth and increases its 
expression via NF-kappaB pathway in RA-FLS. Int. J. Rheum. Dis. 15:322-329. 
54. Garcia-Vicuna, R., M. V. Gomez-Gaviro, M. J. Dominguez-Luis et al (2004) CC and 
CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase 
production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis 
Rheum. 50:3866-3877. 
55. Edhayan, G., R. A. Ohara, W. A. Stinson et al (2016) Inflammatory properties of 
inhibitor of DNA binding 1 secreted by synovial fibroblasts in rheumatoid arthritis. 
Arthritis Res. Ther. 18:87. 
 
 
 
